European Association of Urology Annual Congress (EAU23)

Milan 10 March 2023 - 13 March 2023

Men ‘protected’ regardless of Tx choice for localized prostate cancer

17 May 2023 by

Whatever choice of therapy men with localized prostate cancer may have initially— surgery, radiation, or active monitoring — they would likely have a good 15-year outcome as shown in the ProtecT* trial.

Men ‘protected’ regardless of Tx choice for localized prostate cancer

17 May 2023

Fear of sexual dysfunction due to vasectomy dispelled

27 Apr 2023 by

Men who are considering vasectomy can rest easy knowing that the procedure has no harmful effect on their sexual health, as suggested in a study presented at EAU 2023.

Fear of sexual dysfunction due to vasectomy dispelled

27 Apr 2023

Immune-related AEs tied to improved survival in bladder cancer patients on atezolizumab

27 Apr 2023 by

In patients with locally advanced or metastatic urothelial cancer patients receiving atezolizumab treatment, immune-related adverse events (AEs) were associated with improved survival outcomes, according to an analysis of individual participant data from the IMvigor210 and IMvigor211 studies.

Immune-related AEs tied to improved survival in bladder cancer patients on atezolizumab

27 Apr 2023

Temporary sperm blocker yields exciting results in first-in-human trial

26 Apr 2023 by

Injecting a degradable hydrogel into the vas deferens appears to be a feasible means of birth control for men, leading to sperm-free semen within only 30 days of implantation with a low potential for harm, according to the initial results of a first-in-human clinical trial presented at EAU 2023.

Temporary sperm blocker yields exciting results in first-in-human trial

26 Apr 2023

Urine test predicts bladder cancer risk 12 years prior to symptom onset

24 Apr 2023 by

A simple urine test looking at genetic mutations in DNA predicts urothelial cancer – the most common type of bladder cancer – 12 years before patients develop symptoms in a recent study.

Urine test predicts bladder cancer risk 12 years prior to symptom onset

24 Apr 2023

MV-140 vaccine proven safe, effective in recurrent UTI

18 Apr 2023 by

Immunotherapy with MV-140 (Uromune) successfully prevents urinary tract infections (UTIs) in patients suffering from recurrent UTIs, suggest the results of a prospective study presented at the 38th Annual EAU Congress (EAU 2023).

MV-140 vaccine proven safe, effective in recurrent UTI

18 Apr 2023

Fosfomycin, cefixime prevent infections in prostate biopsy

17 Apr 2023 by

In patients undergoing transrectal ultrasound-guided prostate biopsy, prophylaxis with either fosfomycin or cefixime leads to fewer infectious complications, as shown in a study presented at the 38th Annual EAU Congress (EAU 2023).